| 151 |
9620057 | Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. | 1995 |
1 |
| 152 |
24283686 | Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. | 1995 Sep |
3 |
| 153 |
7835624 | General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. | 1994 Sep |
2 |
| 154 |
7874370 | COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. | 1994 Nov |
2 |
| 155 |
8035933 | The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. | 1994 Jul |
1 |
| 156 |
8039535 | Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. | 1994 |
5 |
| 157 |
8126502 | Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. | 1994 Feb |
1 |
| 158 |
8190296 | Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. | 1994 May |
1 |
| 159 |
8290096 | Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. | 1994 Jan |
1 |
| 160 |
27520516 | Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease. | 1994 Mar |
4 |
| 161 |
8095232 | Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. | 1993 Jan-Feb |
1 |
| 162 |
8112370 | Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. | 1993 |
3 |
| 163 |
8341294 | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. | 1993 Jul |
1 |
| 164 |
8477410 | The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. | 1993 Apr |
5 |
| 165 |
12959293 | The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. | 1993 Nov |
2 |
| 166 |
1463794 | Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. | 1992 Aug |
1 |
| 167 |
1875781 | Catechol-O-methyltransferase and aromatic L-amino acid decarboxylase activities in human gastrointestinal tissues. | 1991 |
2 |
| 168 |
2289048 | L-dopa as substrate for human duodenal catechol-O-methyltransferase and aromatic L-amino acid decarboxylase. | 1990 Nov |
2 |